triazoles has been researched along with Iron Overload in 323 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 87 (26.93) | 29.6817 |
| 2010's | 221 (68.42) | 24.3611 |
| 2020's | 15 (4.64) | 2.80 |
| Authors | Studies |
|---|---|
| Aparicio López, C; Cervera Bravo, Á; Niño Taravilla, C; Otaola Arca, H; Sevilla, J | 1 |
| Cheng, K; Greenway, A; Kaplan, Z; Wu, S; Zargari, A | 1 |
| Babu, T; Panachiyil, GM; Ravi, MD; Sebastian, J | 1 |
| Han, B; Zhang, R | 1 |
| Ahmed, J; Moeed, A; Naeem, U; Rais, H; Saleem, A; Shuja, SH; Waqar, E | 1 |
| Qadah, T | 1 |
| Bova, C; Bruzzese, A; Capodanno, I; Filippelli, G; Gentile, M; Lucia, E; Martino, EA; Mendicino, F; Morabito, F; Neri, A; Olivito, V; Vigna, E | 1 |
| Baker, Z; Dillon, H; Pena, A; Sparks, S; Syed, H; Wang, Y | 1 |
| Aydinok, Y | 1 |
| Kontoghiorghe, CN; Kontoghiorghes, GJ | 2 |
| Buaboonnam, J; Narkbunnam, N; Phuakpet, K; Pongtanakul, B; Sanpakit, K; Takpradit, C; Vathana, N; Viprakasit, V | 1 |
| Allò, M; Campisi, S; Casale, M; Cassinerio, E; Cattoni, A; De Michele, E; Di Concilio, R; Ferrara, F; Forni, GL; Ladogana, S; Lazzarino, AI; Marcon, A; Notarangelo, LD; Origa, R; Pasquali, D; Peluso, A; Perrotta, S; Picariello, S; Poggi, M; Putti, MC; Quarta, A; Renni, R; Roberti, D; Sau, A; Serra, M; Sportelli, F; Sturiale, P; Tartaglione, I | 1 |
| Aboobacker, FN; Abraham, A; Dixit, G; George, B; Korula, A; Lakshmi, KM; Mathews, V; Srivastava, A | 1 |
| Geara, A; Sayani, F; Yui, JC | 1 |
| Etemadfar, P; Ghaedi, M; Ghatee, MA; Moghaddam, AG; Omidifar, N; Rad, F; Zardkhoni, SZ | 1 |
| Ambrogio, AG; Baldini, M; Cassinerio, E; Mancarella, M; Marcon, A; Motta, I | 1 |
| Biliotti, E; Esvan, R; Franchi, C; Palazzo, D; Serani, M; Silvestri, AM; Sorrentino, F; Spaziante, M; Taliani, G; Volpicelli, L | 1 |
| Rose, C | 2 |
| Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK | 1 |
| Kolnagou, A; Kontoghiorghes, GJ | 2 |
| Davies, M; Layton, D; Osborne, V; Shakir, SAW | 1 |
| Shen, JC; Zhang, YC; Zhao, MF | 1 |
| Leitch, HA; Wong, SA | 1 |
| Gattermann, N | 1 |
| Kanamori, H; Kanda, J; Kanda, Y; Koyama, S; Machida, S; Miyazaki, T; Morita, S; Najima, Y; Okamoto, S; Saito, T; Tachibana, T; Takeuchi, M; Tanaka, M; Yamamoto, E | 1 |
| Aydogdu, S; Bayramoglu, Z; Dursun, M; Karagenc, AO; Karakas, Z; Karaman, S; Tugcu, D; Yilmaz, Y | 1 |
| Doery, JC; Kaplan, Z; Kerr, PG; Yii, E | 1 |
| Sivaramakrishnan, G; Sridharan, K | 1 |
| Doree, C; Estcourt, LJ; Fisher, SA; Fortin, PM; Hopewell, S; Madgwick, KV; Trivella, M | 1 |
| Hu, H; Liu, W; Wen, X; Wu, D; Ye, B; Zhou, Y | 1 |
| Hassan, MK; Mohsin, AM | 1 |
| Sari, TT; Wahidiyat, PA; Yosia, M | 1 |
| Cho, B; Chung, NG; Jang, PS; Jeong, DC; Kim, HK; Lee, DH | 1 |
| Alimena, G; Breccia, M | 1 |
| Cid, J; Díaz, M; Palomera, L; Solano, F; Zamora, C | 1 |
| Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL | 1 |
| Ihling, C; Tesch, H | 1 |
| Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, JB; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhang, Y | 1 |
| Kontoghiorghes, GJ | 9 |
| Pongtanakul, B; Viprakasit, V | 1 |
| Butler, J; Curley, C; Durrant, S; Kennedy, GA; Morris, KL; Subramonpillai, E | 1 |
| Cappellini, MD; Caruso, V; Chiavilli, F; Commendatore, F; Forni, GL; Galanello, R; Longo, F; Mulas, S; Musallam, KM; Piga, A; Quarta, G | 1 |
| Brittenham, GM; Olivieri, NF | 1 |
| Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, JB; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhu, Z | 1 |
| Ammirabile, M; Casale, M; Cinque, P; Costantini, S; Di Matola, T; Filosa, A; Prossomariti, L; Ricchi, P; Spasiano, A | 1 |
| Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, M; Habr, D; Kriemler-Krahn, U; St Pierre, TG; Taher, A | 1 |
| Akianidis, V; Christoulas, D; Karavas, A; Komninaka, V; Terpos, E; Voskaridou, E | 1 |
| Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA | 1 |
| Akyol, G; Baldane, S; Cetin, M; Eser, B; Kaynar, L; Keklik, M; Kurnaz, F; Pala, C; Sivgin, S; Unal, A; Zararsiz, G | 1 |
| Belohlavkova, P; Cermak, J; Cervinek, L; Jonasova, A; Neuwirtova, R; Vondrakova, J | 1 |
| Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y | 1 |
| Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ | 1 |
| Bina, P; Cossa, S; Danjou, F; Defraia, E; Dessì, C; Foschini, ML; Galanello, R; Leoni, G; Matta, G; Morittu, M; Origa, R | 1 |
| Cappellini, MD; Taher, AT; Temraz, S | 1 |
| Alizadeh, S; Bamedi, T; Dorgalaleh, A; Jahantigh, A; Naderi, M; Sadeghi-Bojd, S; Tabibian, S; Valeshabad, AK | 1 |
| Habr, D; Huang, SL; Lai, YR; Li, CF; Li, Q; Liu, RR; Martin, N; Shen, ZX | 1 |
| de Witte, T | 1 |
| Toyokuni, S | 1 |
| Chung, J; Jang, JH; Jo, DY; Kim, HJ; Lee, JH; Lee, JW; Yoon, SS | 1 |
| Cheong, JW; Chung, J; Hyun, MS; Jo, DY; Joo, YD; Jung, CW; Kim, BS; Kim, CS; Kim, HJ; Kim, HY; Lee, JH; Lee, KH; Min, YH; Park, CY; Park, HS; Seong, CM; Shim, H; Sohn, SK; Yoon, HJ; Yoon, SS | 1 |
| Bardou-Jacquet, E; Beaumont-Epinette, MP; Ben Ali, Z; Brissot, P; Jouanolle, AM; Loreal, O | 1 |
| Abdollah Gorji, F; Alavi, S; Arzanian, MT; Ebadi, M; Ghazizadeh, F; Shamsian, B | 1 |
| Aydinok, Y; Belhoul, KM; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Lai, Y; Lawniczek, T; Pennell, DJ; Piga, A; Porter, JB; Weisskopf, M; Yesilipek, A; Zhang, Y | 1 |
| Giardini, C; Guiducci, B; Isidori, A; Loscocco, F; Ricciardi, T; Visani, G | 1 |
| Cappellini, MD; Chuncharunee, S; Habr, D; Karakas, Z; Kattamis, A; Origa, R; Porter, JB; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhu, Z | 1 |
| Alimena, G; Angelucci, E; Borin, L; Caocci, G; Cilloni, D; Di Tucci, AA; Fazi, P; Fenu, S; Finelli, C; Latte, G; Molteni, A; Piciocchi, A; Quaresmini, G; Quarta, G; Rivellini, F; Salvi, F; Sanpaolo, G; Santini, V; Storti, S; Tura, S; Vallisa, D; Vignetti, M; Volpe, A; Voso, MT | 1 |
| Coates, TD | 1 |
| Merkel, DG; Nagler, A | 1 |
| Clissa, C; Finelli, C; Stanzani, M | 1 |
| Chan, MR; Elramah, M; Murphy, N; Vats, H; Zhong, W | 1 |
| Cappellini, MD; Cassinerio, E; Duca, L; Fraquelli, M; Orofino, N; Poggiali, E; Roghi, A; Zanaboni, L | 1 |
| Hayakawa, F; Naoe, T; Tomita, A | 1 |
| Plosker, GL; Shirley, M | 1 |
| Chou, HC; Hsiao, FY; Huang, WF; Tsai, YW | 1 |
| Hikota, R; Horiuchi, T; Kato, S; Kimura, F; Kobayashi, A; Kobayashi, S; Maekawa, T; Osawa, Y; Sato, K; Watanabe, J; Yamamura, T | 1 |
| Batlle, M; Belloch, V; Duarte, R; Hernández, D; Jarque, I; Jiménez, M; Jiménez, S; López, J; Rovira, M; Sampol, A; Solano, C; Valcárcel, D; Vallejo, C; Vázquez, L | 1 |
| Díaz-García, JD; Gallegos-Villalobos, A; Gonzalez-Espinoza, L; Ortiz, A; Sanchez-Niño, MD; Villarrubia, J | 1 |
| Atipas, S; Kusuwan, T; Limviriyakul, S; Pooliam, J; Sangpraypan, T; Tanphaichitr, A; Tanphaichitr, VS; Viprakasit, V | 1 |
| Gadong, N; Hemmaway, C; Kaya, B; Newell, H; Simmons, A; Telfer, P; Tsouana, E; Whitmarsh, S | 1 |
| Alfonso, P; Andrade-Campos, M; Andreu, V; Gervas-Arruga, J; Giraldo, P; Irun, P; Medrano-Engay, B; Pocovi, M | 1 |
| Amendola, G; Casale, M; Cinque, P; Citarella, S; De Michele, E; Della Rocca, F; Filosa, A; Nobili, B; Palmieri, F; Perrotta, S; Pugliese, U; Ragozzino, A; Tartaglione, I | 1 |
| Chen, CH; Shu, KH; Yang, Y | 1 |
| Aydinok, Y; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Lai, YR; Musallam, KM; Pennell, DJ; Piga, A; Porter, JB; Shen, J; Yesilipek, A | 1 |
| Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Massano, D; Piga, A | 1 |
| Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK | 1 |
| Bouillaud, E; Cappellini, MD; Forni, GL; Fracchia, S; Habr, D; Hirschberg, R; Lai, ME; Piga, A; Wegener, A | 1 |
| Cappellini, MD; Cassinerio, E; Consonni, D; Giuditta, M; Orofino, N; Pedrotti, P; Poggiali, E; Roghi, A; Zanaboni, L | 1 |
| Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y | 1 |
| Ballas, SK; Cançado, R; Chiattone, C; de Moraes Bastos, R; Guerra-Shinohara, EM; Melo, MR; Santos, PC | 1 |
| Cappellini, MD; Chan, LL; El-Alfy, M; El-Ali, A; Giraudier, S; Han, J; Lai, Y; Porter, JB; Viprakasit, V | 1 |
| Alimena, G; Aloe Spiriti, MA; Breccia, M; Buccisano, F; Fenu, S; Maurillo, L; Tafuri, A; Voso, MT | 1 |
| Bae, SH; Chung, JS; Hyun, MS; Joo, YD; Kim, H; Kim, HG; Kim, IH; Kim, SH; Kim, YS; Kwon, KY; Lee, GW; Lee, HS; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, KT; Ryoo, HM; Sohn, SK | 1 |
| Aloe Spiriti, MA; Breccia, M; Buccisano, F; Criscuolo, M; D'Addosio, A; Fenu, S; Fragasso, A; Latagliata, R; Maurillo, L; Musto, P; Niscola, P; Piccioni, AL; Refrigeri, M; Tatarelli, C; Trapè, G; Venditti, A; Voso, MT | 1 |
| Attri, SV; Bansal, D; Bhatia, P; Marwaha, RK; Totadri, S; Trehan, A | 1 |
| Aydinok, Y; Cappellini, MD; Constantinovici, N; El-Beshlawy, A; Elalfy, M; Habr, D; Karakas, Z; Kattamis, A; Kilinç, Y; Origa, R; Perrotta, S; Porter, JB; Shen, J; Viprakasit, V | 1 |
| Bhathal, P; Doyle, A; Rusli, F | 1 |
| Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC | 1 |
| Chiang, PH; Kuo, PH; Lai, CW; Lin, KH; Lu, MY; Wang, N; Wu, TH; Wu, WH | 1 |
| Ansari, S; Arandi, N; Azarkeyvan, A; Bordbar, M; Haghpanah, S; Karimi, M; Safaei, S | 1 |
| Angelucci, E | 1 |
| Agaoglu, L; Glaser, S; Kilinç, Y; Kohgo, Y; Lim, LC; Miyamura, K; Urabe, A; Wang, C; Warzocha, K; Wiktor-Jedrzejczak, W | 1 |
| Alta, RY; Espósito, BP; Goswami, D; Machini, MT; Nomura, CS; Silvestre, DM; Vitorino, HA | 1 |
| Agapidou, A; Boura, P; Klonizakis, P; Mavroudi, M; Spanos, G; Vetsiou, E; Vlachaki, E | 1 |
| Hagag, AA; Hamam, MA; Hazaa, SM; Taha, OA | 1 |
| Adil, SN; Shaikh, MS | 1 |
| Baer, MR; Davidoff, AJ; Friedmann, E; Gore, SD; Hendrick, F; Paley, C; Sasane, M; Zeidan, AM | 1 |
| Alimena, G; Andriani, A; Bagnato, A; Breccia, M; Cedrone, M; Ciccone, F; De Muro, M; Di Veroli, A; Latagliata, R; Leonetti, SC; Maurillo, L; Montagna, C; Montanaro, M; Montefusco, E; Niscola, P; Porrini, R; Rago, A; Spadea, A; Spirito, F | 1 |
| Chang, HH; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Peng, SS; Yang, YL | 1 |
| D'Ascola, DG; Fragomeno, C; Roccabruna, E | 1 |
| El Rassi, F; Saliba, AN; Taher, AT | 1 |
| Marsella, M; Ricchi, P | 1 |
| Escudero-Vilaplana, V; Garcia-Gonzalez, X; Osorio-Prendes, S; Romero-Jimenez, RM; Sanjurjo-Saez, M | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S | 1 |
| Aydinok, Y; Cappellini, MD; Joaquin, V; Karakas, Z; Kattamis, A; Lai, YR; Porter, JB; Siritanaratkul, N; Taher, AT; Uwamahoro, MJ; Viprakasit, V; Wang, C; Zhu, Z | 1 |
| Chang, H; Hu, D; Hu, L; Huang, J; Liu, F; Nie, N; Quan, R; Shao, Y; Shi, J; Tang, X; Xiao, H; Zhang, F; Zhang, J; Zhang, L; Zheng, C; Zheng, Y; Zhou, Y | 1 |
| Corpino, M; Dessì, C; Foschini, ML; Leoni, G; Moi, P; Morittu, M; Origa, R; Zappu, A | 1 |
| Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V | 1 |
| Angelucci, E; Pilo, F | 1 |
| Gomber, S; Jain, P; Narang, M; Sharma, S | 1 |
| Arora, S; Athale, UH; Bhatt, MD; Kirby-Allen, M; Papneja, K; Wiernikowski, JT | 1 |
| Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Massano, D; Piga, A; Pirro, E | 1 |
| Chattipakorn, N; Chattipakorn, SC; Krintratun, W; Sripetchwandee, J; Wongjaikam, S | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Sripetchwandee, J; Wongjaikam, S | 1 |
| Bruch, HR; Dencausse, Y; Heßling, J; Michl, G; Schlag, R; Schneider-Schranz, C; Schulte, C; Skorupa, A; Tesch, H; Wolf, S | 1 |
| Badcock, CA; Bowden, DK; Brown, G; Gervasio, OL; Grigg, A; Ho, PJ; Marlton, P; St Pierre, T; Tay, L; Teo, J; Traficante, R | 1 |
| Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F | 1 |
| Abbas, HA; Cappellini, MD; Inati, A; Kahale, M; Koussa, S; Musallam, KM; Nasr, TA; Porter, JB; Sbeiti, N; Taher, AT | 1 |
| Arboscello, E; Biale, L; Del Corso, L; Filiberti, R; Parodi, EL; Russo, R | 1 |
| Chuansumrit, A; Kadegasem, P; Khlairit, P; Mahachoklertwattana, P; Pengpis, P; Poomthavorn, P; Sirachainan, N; Sungkarat, W; Wongwerawattanakoon, P | 1 |
| Aydinok, Y; El-Ali, A; El-Beshlawy, A; Elalfy, M; Han, J; Lee, SH; Porter, JB; Sutcharitchan, P; Taher, A | 1 |
| Atilla, E; Demirer, T; Toprak, SK | 1 |
| Brewster, UC; McPhedran, P; Yusuf, B | 1 |
| Kohgo, Y; Kojima, S; Matsumura, I; Miyazaki, Y; Nakao, S; Niitsu, Y; Ohyashiki, K; Ozawa, K; Suzuki, T; Tomonaga, M | 1 |
| Hata, T; Ishikawa, T; Kato, J; Kondo, M; Miyazawa, K; Mori, H; Nakao, S; Ohyashiki, K; Omine, M; Ozawa, K; Rojkjaer, L; Taniguchi, J; Tanii, H; Tatsumi, Y; Urabe, A | 1 |
| Brosnahan, G; Gokden, N; Swaminathan, S | 1 |
| Cappellini, MD; Taher, A | 2 |
| Dinter, D; Dorn-Beineke, A; Hastka, J; Hehlmann, R; Leismann, O; Lutz, K; Metzgeroth, G; Schultheis, B | 1 |
| Deeren, D | 1 |
| Arruga, F; Cilloni, D; Messa, E; Messa, F; Roetto, A; Saglio, G | 1 |
| Brewer, C; Gonzalez, I; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Cappellini, MD | 2 |
| Bernhardt, MB; Mahoney, DH; Mueller, BU; Raphael, JL | 1 |
| Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A | 1 |
| Daar, S; Habr, D; Hmissi, A; Kriemler-Krahn, U; Nick, H; Pathare, A; Taher, A | 1 |
| Capalbo, S; Franzese, MG; Palumbo, G; Spinosa, G | 1 |
| Baumgartner, C; Nösslinger, T; Pfeilstöcker, M; Sperr, WR; Valent, P; Wimazal, F | 1 |
| Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Taher, A | 1 |
| Kim, DM; Neupane, GP | 1 |
| Cappellini, MD; Pattoneri, P | 1 |
| Ozawa, K | 1 |
| Al-Rousan, RM; Blough, ER; Gutta, AK; Kakarla, SK; Laurino, JP; Paturi, S; Walker, EM | 1 |
| Imran, F; Phatak, P | 1 |
| Stone, RM; Tefferi, A | 1 |
| Arrizabalaga, B; Del Cañizo, C; Remacha, AF; Sanz, G; Villegas, A | 1 |
| Bergmann, AK; Braunstein, J; Chirnomas, D; Finkelstein, Y; Grant, FD; Neufeld, EJ; Paley, C; Pereira, L; Shannon, M; Smith, AL | 1 |
| Alvarez, O; Lewis, N; Lopez-Mitnik, G; Paley, C; Pow Sang, CD; Robinson, N; Rodriguez-Cortes, H | 1 |
| Cappellini, MD; Clark, J; Galanello, R; Habr, D; Lawniczek, T; Piga, A; Porter, JB; Taher, A; Vichinsky, E | 1 |
| Daar, S; Pathare, A; Taher, A | 1 |
| Chan, GC; Chan, S; Ha, SY; Ho, PL | 1 |
| Efstathiou, A; Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ; Michaelides, Y | 1 |
| Fibach, E; Prus, E | 1 |
| Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, M; Gattermann, N; Giraudier, S; Habr, D; Kattamis, A; Lee, JW; Li, CK; Lin, KH; Porter, J; Rose, C; Roubert, B; Seymour, JF; Taher, A; Thein, SL; Viprakasit, V | 1 |
| Aydinok, Y; Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, MS; Habr, D; Ibrahim, H; Kattamis, A; Li, CK; Pennell, DJ; Porter, JB; Roubert, B; Smith, G; Sutcharitchan, P; Taher, A; Viprakasit, V | 1 |
| Porter, JB | 4 |
| HATANO, K; MATSUYAMA, T; MORI, M; MUROI, K; NAGAI, T; OKABE, H; OMORI, T; OZAWA, K; QZAKI, K; SUZUKI, T; TOSHIMA, M; UEDA, M; UEHARA, E | 1 |
| Becker-Cohen, R; Even-Or, E; Miskin, H | 1 |
| Ammirabile, M; Cinque, P; Costantini, S; Di Matola, T; Prossomariti, L; Ricchi, P; Spasiano, A | 1 |
| Burns, LJ; Lazarus, HM; Majhail, NS | 1 |
| Bruin, GJ; Glaenzel, U; Hazell, K; Porter, JB; Sechaud, R; Waldmeier, F; Warrington, S | 1 |
| Schmid, M | 1 |
| Fujita, T; Haba, R; Nishiuchi, T; Ohnishi, H; Okutani, Y; Yoshida, K | 1 |
| Ampe, E; Galanti, L; Hecq, JD; Karmani, L; Lebitasy, M; Nick, H | 1 |
| Huang, XP; Spino, M; Templeton, DM; Thiessen, JJ | 1 |
| Borsellino, Z; Cuccia, L; Gagliardotto, F; Marocco, MR; Ruffo, GB; Tarantino, R | 1 |
| Arvapalli, RK; Blough, ER; Gadde, MK; Kakarla, SK; Katta, A; Laurino, JP; Paturi, S; Rice, KM; Walker, EM; Wehner, P; Wu, M | 1 |
| Fausel, CA | 1 |
| Bouchet, S; Chauzit, E; Mahon, FX; Micheau, M; Molimard, M; Moore, N; Titier, K | 1 |
| Fibach, E; Ghoti, H; Grisariu, S; Merkel, D; Perez-Avraham, G; Rachmilewitz, EA | 1 |
| Coates, TD; Giardina, P; Glynos, T; Harmatz, P; Kang, BP; Paley, C; Thompson, A; Wood, JC | 2 |
| Al Jefri, A; Al Zir, K; Baladi, JF; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Kriemler-Krahn, U; Rofail, D; Taher, A | 1 |
| Domokos, G; Fenaux, P; Finelli, C; Ganser, A; Gattermann, N; Guerci-Bresler, A; Habr, D; Porta, MD; Rose, C; Roubert, B; Schmid, M; Taylor, K; Vassilieff, D | 1 |
| Bertrand, DM; Eas, F; Godin, M; Grangé, S; Guerrot, D | 1 |
| Jetsrisuparb, A; Jetsrisuparb, C; Komvilaisak, P; Wiangnon, S | 1 |
| Balocco, M; Carrara, P; Forni, GL; Pinto, V | 1 |
| Kolnagou, A; Kontoghiorghes, GJ; Petrikkos, G; Skiada, A | 1 |
| Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K | 1 |
| Karasu, G; Kazik, M; Ozturk, Z; Uygun, V; Yesilipek, MA | 1 |
| Cabantchik, ZI; Glynos, T; Greenberg, PL; Koller, CA; Paley, C; Schiffer, C; Warsi, G | 1 |
| Christoulas, D; Dimopoulou, M; Douskou, M; Mpoutou, E; Plata, E; Sioni, A; Terpos, E; Voskaridou, E | 1 |
| Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Niemeyer, C; Rücker, G | 1 |
| Hershko, C | 2 |
| Leitch, HA | 1 |
| Inati, A; Khoriaty, E; Musallam, KM; Taher, AT | 1 |
| Bozkaya, D; Li, Q; Migliaccio-Walle, K; Miranda, E; Oliver, N; Tolley, K | 1 |
| Adams, PC; Bonkovsky, HL; Brissot, P; Griffel, L; Gross, J; Lynch, N; Malfertheiner, P; McLaren, GD; Niederau, C; Phatak, P; Pietrangelo, A; Piperno, A; Powell, LW; Russo, MW; Stoelzel, U; Stremmel, W; Wurster, M; Zhang, Y | 1 |
| Im, HJ; Kim, BE; Koh, KN; Park, M; Seo, JJ | 1 |
| Bisconte, MG; Capra, M; Caruso, V; Cianciulli, P; Filosa, A; Lippi, A; Lombardi, M; Maggio, A; Malaventura, C; Meloni, A; Midiri, M; Missere, M; Pepe, A; Pitrolo, L; Positano, V; Prossomariti, L; Putti, MC; Quarta, A; Romeo, MA; Rossi, G | 1 |
| Al-Rousan, R; Arvapalli, RK; Blough, ER; Fannin, J; Kakarla, SK; Katta, A; Liu, H; Paturi, S; Rice, KM; Triest, WE; Wang, Y; Wu, M | 1 |
| Berdousi, H; Gotsis, E; Kattamis, A; Ladis, V | 1 |
| Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G | 2 |
| Aydinok, Y; Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, MS; Habr, D; Ibrahim, H; Kattamis, A; Li, CK; Pennell, DJ; Porter, JB; Roubert, B; Smith, G; Taher, A; Viprakasit, V | 2 |
| Cançado, RD; Chiattone, CS; Guerra-Shinohara, EM; Krieger, JE; Pereira, AC; Santos, PC | 1 |
| Chang, HH; Chang, TT; Chiou, SS; Jou, ST; Liao, YM; Lin, DT; Lin, KH; Lin, PC; Lu, MY; Yang, YL | 1 |
| Porter, JB; Shah, FT | 1 |
| Cheng, CH; Lo, FS; Wei, HY; Yang, CP | 1 |
| Eldem, G; Gumruk, F; Hazirolan, T; Unal, S | 1 |
| Buchbinder, D; Hsieh, L; Nugent, D; Puthenveetil, G; Soni, A; Stites, J; Vu, D | 1 |
| Brittenham, GM | 1 |
| Chandra, J; Chaudhary, H; Dutta, AK; Pemde, H; Singh, V | 1 |
| Melpignano, A; Quarta, A; Quarta, G | 1 |
| Bechtel, H; Kashtan, CE; Neglia, JP; Rheault, MN | 1 |
| Chao, NJ; Kanda, J; Kawabata, H | 1 |
| Fibach, E; Ganz, T; Ghoti, H; Gordana, O; Rachmilewitz, EA; Westerman, M | 1 |
| Al-Rousan, RM; Blough, ER; Katta, A; Laurino, J; Rice, KM; Triest, WE; Walker, EM; Wu, M | 1 |
| Bernaudin, F; Coates, T; Deng, W; Forni, GL; Gardner, R; Giannone, V; Griffel, L; Hassell, K; Heeney, MM; Inusa, B; Kutlar, A; Lane, P; Mathias, L; Porter, J; Tebbi, C; Vichinsky, E; Wilson, F | 1 |
| Christoulas, D; Terpos, E; Voskaridou, E | 1 |
| Beris, P; Domokos, G; Forni, GL; Habr, D; Lin, KH; Porter, JB; Roubert, B; Taher, A; Thein, SL | 1 |
| Chen, GF; Chen, JJ; Gao, HY; Li, CG; Li, Q | 1 |
| Musallam, KM; Taher, AT | 1 |
| Ahmed, J; Jankharia, B; Krishnan, P; Merchant, R | 1 |
| El-Beshlawy, A; Evangeli, M; Porter, JB | 1 |
| Blumenstengel, K; Gattermann, N; Germing, U; Goebeler, M; Groschek, M; Jarisch, A; Junkes, A; Leismann, O; Losem, C; Procaccianti, M; Schlag, R | 1 |
| Bahcebasi, S; Cetin, M; Deniz, K; Eser, B; Kaynar, L; Kurnaz, F; Ozturk, A; Pala, C; Sivgin, S; Unal, A; Uzer, E | 1 |
| Alvarez, O; Cohen, AR; Garro, J; Kwiatkowski, JL; Lane, P; Mortier, N; Mueller, B; Nagasubramanian, R; Sarnaik, S; Schultz, W; Thompson, A; Ware, RE; Woods, GM; Yovetich, N | 1 |
| Campus, S; Galanello, R; Origa, R | 1 |
| Sinakos, E; Tsapas, A; Vlachaki, E | 1 |
| Suzuki, T | 2 |
| Kato, J; Matsuki, E; Matsumoto, K; Nakaya, A; Okamoto, S; Yamane, A | 1 |
| Fernandes, JL | 1 |
| Della Porta, M; Fenaux, P; Finelli, C; Gattermann, N; Guerci-Bresler, A; Habr, D; Marcellari, A; Rose, C; Roubert, B; Schmid, M; Stadler, M; Taylor, K; Vassilieff, D | 1 |
| Bae, SJ; Chueh, HW; Kang, C; Koo, HH; Lee, SH; Son, MH; Sung, KW; Yoo, KH | 1 |
| Azik, FM; Culha, V; Kara, A; Karakurt, N; Ozkasap, S; Tavil, B; Tunç, B; Yarali, N | 1 |
| Hayashi, H; Maeda, H; Naoe, T; Ohashi, H; Saito, H; Tomita, A | 1 |
| Cochat, P; Dubourg, L; Hadj-Aïssa, A; Laurain, C; Pondarré, C; Ranchin, B; Sigaudo-Roussel, D | 1 |
| Araki, H; Hara, T; Moriwaki, H; Oyama, M; Tsurumi, H; Yoshikawa, T | 1 |
| Chen, YM; Huang, CC; Kuo, CC; Tsai, CW; Yang, FJ | 1 |
| Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ | 1 |
| Gaur, A | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, J; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhang, Y | 1 |
| Arnold, L; Kurtin, SE; Lindroos-Kolqvist, P; Shah, J; Tinsley, S | 1 |
| Hayashi, T; Iyama, S; Kaneko, Y; Kato, J; Kawano, Y; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Ono, K; Sato, T; Sato, Y; Takada, K; Takimoto, R | 1 |
| Brewer, C; Lykkesfeldt, J; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Bruniera, P; Cancado, R; Chiattone, C; de Moraes Bastos, R; Olivato, MC; Rezende Melo, M; Szarf, G | 1 |
| Marks, PW | 1 |
| Cappellini, MD; Hoffbrand, AV; Taher, A | 1 |
| Agapidou, A; Economou, M; Efthimia, V; Neokleous, N; Perifanis, V; Teli, A; Vetsiou, E | 1 |
| Chandiwana, D; Karnon, J; Tolley, K; Vieira, J | 1 |
| Baier, M; Gattermann, N; Giagounidis, A; Haase, D; Höchsmann, B; Hofmann, WK; Junkes, A; Leismann, O; Lübbert, M; Lück, A; Nolte, F; Platzbecker, U; Schrezenmeier, H; Schumann, C; Taupitz, M | 1 |
| Aydinok, Y; Chan, LL; El-Beshlawy, A; Elalfy, MS; Habr, D; Lee, SH; Martin, N; Porter, JB; Sutcharitchan, P; Taher, AT | 1 |
| Evans, P; Harmatz, P; Kurio, G; Lal, A; Neumayr, L; Ng, V; Porter, J; Sweeters, N; Vichinsky, E | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Yahng, SA | 1 |
| Azarkeivan, A; Bordbar, MR; Cohan, N; Haghpanah, S; Karimi, M; Zareifar, S | 1 |
| Ruivard, M | 1 |
| Bekiari, E; Mainou, M; Tsapas, A; Vetsiou, E; Vlachaki, E | 1 |
| Javanbakht, M; Karimi, M; Keshtkaran, A; Mashayekhi, A; Nuri, B; Salavati, S | 1 |
| Braulke, F; Haase, D; Hartmann, J; Konietschke, F; Maas, JH; Sinzig, U; Wulf, G | 1 |
| Batty, KT; Ferrari, P; Maker, GL; Olynyk, JK; Siva, B; Trengove, RD | 1 |
| Acklin, P; Faller, B; Hauffe, S; Jin, Y; Lattmann, R; Nick, H; Schnebli, HP; Sergejew, T; Thomas, H; Wong, A | 1 |
| Alberti, D; Anderson, JR; Giardina, PJ; Grady, RW; Krebs-Brown, AJ; Nathan, DG; Neufeld, EJ; Nisbet-Brown, E; Olivieri, NF; Séchaud, R; Sizer, KC | 1 |
| Cabantchik, ZI; Hershko, CM; Konijn, AM; Link, GM | 1 |
| El Beshlawy, A | 1 |
| Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ | 1 |
| Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G | 1 |
| Galanello, R | 1 |
| Fischer, R; Harmatz, P; Nielsen, P; Piga, A | 1 |
| Greenberg, PL | 1 |
| Neufeld, EJ | 1 |
| Hagemann, TM; Vanorden, HE | 1 |
| Fischer, R | 1 |
| Alberti, D; Bordone, E; Cappellini, MD; Donato, G; Ford, JM; Forni, GL; Galanello, R; Hewson, N; Lavagetto, A; Opitz, H; Origa, R; Piga, A; Sechaud, R; Zanaboni, L; Zappu, A | 1 |
| Aguilar, MI; Gonzalez, I; Moats, R; Nelson, M; Nick, H; Otto-Duessel, M; Shimada, H; Wood, JC | 1 |
| Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F | 1 |
| Al-Fayoumi, S; Castillo, S; Chakraborti, T; Choudary, J; Frankewich, R; Kacuba, A; Pazdur, R; Rieves, D; Robie-Suh, K; Shashaty, G; Weiss, K | 1 |
| Barton, JC | 1 |
| Stumpf, JL | 1 |
| Baladi, JF; Coates, TD; Delea, TE; Phatak, PD; Sofrygin, O; Thomas, SK | 1 |
| Aguilar, M; Moats, R; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Maggio, A | 1 |
| Abetz, L; Abish, S; Agaoglu, L; Baladi, JF; Bejaoui, M; Cappellini, MD; Cario, H; Coates, T; Ferster, A; Girot, R; Jeng, M; Lai, ME; Loggetto, S; Mangiagli, A; Opitz, H; Porter, J; Ressayre-Djaffer, C; Rofail, D; Strauss, G; Vichinsky, E; Watman, N; Zoumbos, N | 1 |
| Choudhry, VP; Naithani, R | 1 |
| Bernhardt, PV | 1 |
| Drago, V; Foster, P; Heilman, KM; Schmalfuss, IM; Skidmore, FM; Streiff, RR | 1 |
| Keam, SJ; Keating, GM; Yang, LP | 1 |
| Cohen, AR; Glimm, E; Porter, JB | 1 |
| Goldberg, SL | 1 |
| Lindsey, WT; Olin, BR | 1 |
| Vichinsky, E | 1 |
| Alberti, D; Balez, S; Belleli, R; Cappellini, MD; Dutreix, C; Ford, JM; Forni, GL; Galanello, R; Origa, R; Piga, A; Rivière, GJ; Séchaud, R; Zappu, A | 1 |
| Bring, P; Ford, JA; Partovi, N; Yoshida, EM | 1 |
| Ohyashiki, K | 1 |
| Kwiatkowski, JL | 1 |
| Angelucci, E; Barosi, G; Camaschella, C; Cappellini, MD; Cazzola, M; Galanello, R; Marchetti, M; Piga, A; Tura, S | 1 |
| Bardou-Jacquet, E; Brissot, P; Deugnier, Y; Jouanolle, AM; Le Lan, C; Loréal, O; Troadec, MB | 1 |
| Akehurst, R; Jewitt, K; Karnon, J; Ossa, D; Oyee, J; Tolley, K | 1 |
| Forgiarini, P; Schnebli, HP; Sergejew, T | 1 |
| Breuer, W; Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G; Nick, HP | 1 |
| Humbert, H; Mangoni, P; Marfil, F; Maurer, G; Rouan, MC; Séchaud, R | 1 |
84 review(s) available for triazoles and Iron Overload
| Article | Year |
|---|---|
No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2023 |
Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Triazoles | 2022 |
Iron chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2023 |
Combination chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Quality of Life; Triazoles | 2023 |
Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases.
Topics: Animals; Humans; Iron; Iron Overload; Medicine; Metals; Oxidative Stress; Triazoles | 2020 |
Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload.
Topics: Adult; Benzoates; Deferasirox; Fanconi Syndrome; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2021 |
[Transfusions in myelodysplastic syndromes].
Topics: Benzoates; Blood Grouping and Crossmatching; Combined Modality Therapy; Deferasirox; Erythrocyte Transfusion; Hematinics; Hemoglobins; Hepcidins; Humans; Intestinal Absorption; Iron Chelating Agents; Iron Overload; Iron, Dietary; Myelodysplastic Syndromes; Patient Satisfaction; Quality of Life; Rh Isoimmunization; Triazoles | 2017 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Patient Satisfaction; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Triazoles | 2017 |
Iron overload in myelodysplastic syndromes (MDS).
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Erythropoiesis; Hepcidins; Humans; Intestinal Mucosa; Iron; Iron Chelating Agents; Iron Overload; Liver; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2018 |
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Silymarin; Thalassemia; Triazoles | 2018 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Patient Compliance; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2018 |
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report.
Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans; Indonesia; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Pyridones; Thalassemia; Triazoles | 2018 |
Efficacy and safety of deferasirox in myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Clinical Trials, Phase II as Topic; Deferasirox; Drug Eruptions; Drug Therapy, Combination; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Multicenter Studies as Topic; Myelodysplastic Syndromes; NF-kappa B; Oxidative Stress; Prospective Studies; Retrospective Studies; Survival Analysis; Transfusion Reaction; Triazoles | 2013 |
Management of the thalassemias.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Pancreas; Pituitary Gland, Anterior; Pyridones; Thalassemia; Triazoles | 2013 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Thalassemia; Transfusion Reaction; Triazoles | 2013 |
Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Transfusion Reaction; Triazoles | 2013 |
Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis.
Topics: Adsorption; Animals; Asbestos; Asbestosis; Benzoates; Carcinogens, Environmental; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Comparative Genomic Hybridization; Deferasirox; Ferric Compounds; Ferric Oxide, Saccharated; Genes, p16; Glucaric Acid; Humans; Iron Chelating Agents; Iron Overload; Japan; Kidney Neoplasms; Male; Mesothelioma; Mineral Fibers; Peritoneal Neoplasms; Phlebotomy; Pleural Neoplasms; Rats; Triazoles | 2014 |
Non-HFE hemochromatosis: pathophysiological and diagnostic aspects.
Topics: Alcohol Drinking; Benzoates; Biopsy; Cataract; Cation Transport Proteins; Decision Trees; Deferasirox; Diet; Gaucher Disease; Genetic Testing; Hemochromatosis; Hemochromatosis Protein; Hepcidins; Histocompatibility Antigens Class I; Humans; Inflammation; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Iron Overload; Liver; Macrophage Activation Syndrome; Magnetic Resonance Imaging; Membrane Proteins; Metabolic Syndrome; Mutation; Phlebotomy; Receptors, Transferrin; Transferrin; Triazoles | 2014 |
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyridones; Triazoles | 2014 |
A case report of deferasirox-induced kidney injury and Fanconi syndrome.
Topics: Benzoates; Deferasirox; Fanconi Syndrome; Humans; Iron Chelating Agents; Iron Overload; Male; Renal Insufficiency; Triazoles; Young Adult | 2013 |
Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Triazoles | 2014 |
Deferasirox nephrotoxicity-the knowns and unknowns.
Topics: Acute Kidney Injury; Benzoates; Deferasirox; Glomerular Filtration Rate; Humans; Iron Chelating Agents; Iron Overload; Renal Insufficiency, Chronic; Transfusion Reaction; Triazoles | 2014 |
Deferasirox for managing iron overload in people with myelodysplastic syndrome.
Topics: Benzoates; Chelation Therapy; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2014 |
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.
Topics: Benzoates; Blood Platelets; Chelation Therapy; Deferasirox; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Leukocytes; Myelodysplastic Syndromes; Triazoles | 2015 |
Aceruloplasminaemia: a rare but important cause of iron overload.
Topics: Adult; Benzoates; Ceruloplasmin; Chelation Therapy; Deferasirox; Disease Progression; Early Diagnosis; Ferritins; Humans; Iron Chelating Agents; Iron Metabolism Disorders; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Neurodegenerative Diseases; Treatment Outcome; Triazoles | 2015 |
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Pregnancy; Pyridones; Triazoles | 2016 |
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Biomarkers; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Syndrome; Thalassemia; Treatment Outcome; Triazoles | 2015 |
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia; Triazoles | 2016 |
Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major.
Topics: Animals; Benzoates; beta-Thalassemia; Deferasirox; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2016 |
Fanconi Syndrome Secondary to Deferasirox in Diamond-Blackfan Anemia: Case Series and Recommendations for Early Diagnosis.
Topics: Adolescent; Adult; Aged; Anemia, Diamond-Blackfan; Benzoates; Blood Transfusion; Child; Deferasirox; Electrolytes; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles | 2016 |
In brief: Jadenu--a new formulation of deferasirox for iron overload.
Topics: Administration, Oral; Animals; Benzoates; Chemistry, Pharmaceutical; Clinical Trials as Topic; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2016 |
Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation.
Topics: Benzoates; Deferasirox; Ferritins; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Iron Overload; Survival Rate; Triazoles | 2017 |
Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.
Topics: Asian People; Benzoates; Bone Marrow Diseases; Data Collection; Deferasirox; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Japan; Practice Guidelines as Topic; Syndrome; Triazoles | 2008 |
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
Topics: Administration, Oral; Benzoates; Clinical Trials as Topic; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Transfusion Reaction; Triazoles | 2008 |
Long-term efficacy and safety of deferasirox.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2008 |
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
Topics: Administration, Oral; Benzoates; Deferasirox; Erythrocyte Transfusion; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2009 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2009 |
[Pathogenesis of transfusional iron overload and iron chelation therapy].
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Drug Design; Erythrocyte Transfusion; Humans; Iron; Iron Chelating Agents; Iron Overload; Practice Guidelines as Topic; Transferrin; Triazoles | 2009 |
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
Topics: Adolescent; Adult; Anemia; Benzoates; Child; Child, Preschool; Creatinine; Deferasirox; Drug Administration Schedule; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2009 |
Deferasirox: an update.
Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Transfusion Reaction; Treatment Outcome; Triazoles | 2009 |
Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
Topics: Aged; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Platelet Transfusion; Treatment Outcome; Triazoles | 2009 |
Iron chelation therapy in MDS: what have we learnt recently?
Topics: Benzoates; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2009 |
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Interactions; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Myocardium; Pyridones; Triazoles | 2010 |
Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Randomized Controlled Trials as Topic; Triazoles | 2010 |
Deferasirox for managing iron overload in people with myelodysplastic syndrome.
Topics: Benzoates; Chelation Therapy; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2010 |
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2010 |
Iron-chelating therapy for transfusional iron overload.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Practice Guidelines as Topic; Triazoles | 2011 |
Iron overload and allogeneic hematopoietic stem-cell transplantation.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Transplantation, Homologous; Triazoles | 2011 |
Iron chelation therapy for transfusional iron overload: a swift evolution.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles | 2011 |
Deferasirox: pharmacokinetics and clinical experience.
Topics: Animals; Benzoates; Clinical Trials as Topic; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Iron, Dietary; Transfusion Reaction; Triazoles | 2012 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Randomized Controlled Trials as Topic; Thalassemia; Triazoles | 2012 |
[Iron overload and iron chelation therapy].
Topics: Benzoates; Deferasirox; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2012 |
Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Double-Blind Method; Drug Therapy, Combination; Forecasting; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Practice Guidelines as Topic; Prospective Studies; Pyridones; Randomized Controlled Trials as Topic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left | 2012 |
Iron mobilization using chelation and phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Thalassemia; Triazoles | 2012 |
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Phlebotomy; Pyridones; Siderophores; Transfusion Reaction; Triazoles | 2012 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Myelodysplastic Syndromes; Myocardium; Pyridones; Siderophores; Triazoles | 2013 |
Iron-chelating therapy with the new oral agent ICL670 (Exjade).
Topics: Administration, Oral; Animals; Benzoates; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2005 |
Monitoring and treatment of iron overload: state of the art and new approaches.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemosiderin; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Magnetics; Pyridones; Triazoles | 2005 |
Treating iron overload: the state of the art.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Survival Analysis; Triazoles | 2005 |
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia; Thiazoles; Triazoles | 2005 |
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2005 |
Objectives and mechanism of iron chelation therapy.
Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Mitochondria, Heart; Mononuclear Phagocyte System; Pyridones; Rats; Thalassemia; Transfusion Reaction; Triazoles | 2005 |
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Pyridones; Retrospective Studies; Thalassemia; Triazoles | 2005 |
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2006 |
Deferasirox (Exjade): a new iron chelator.
Topics: Benzoates; Deferasirox; Drug Costs; Humans; Iron Chelating Agents; Iron Overload; Orphan Drug Production; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis; Deferasirox; Deferiprone; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2006 |
Deferasirox--an oral agent for chronic iron overload.
Topics: Benzoates; Clinical Trials as Topic; Deferasirox; Drug Interactions; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2006 |
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Forecasting; Hemochromatosis; Humans; Hydroxyethyl Starch Derivatives; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Starch; Thalassemia; Thiazoles; Transfusion Reaction; Triazoles | 2006 |
Deferasirox: An effective once-daily orally active iron chelator.
Topics: Administration, Oral; Animals; Benzoates; Deferasirox; Drug Administration Schedule; Humans; Iron Chelating Agents; Iron Overload; Molecular Structure; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2007 |
Deferasirox.
Topics: Adult; Benzoates; Child; Deferasirox; Deferoxamine; Hematologic Diseases; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Patient Compliance; Siderophores; Transfusion Reaction; Triazoles | 2007 |
Light and shadows in the iron chelation treatment of haematological diseases.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Liver; Pyridones; Triazoles | 2007 |
Current status of iron overload and chelation with deferasirox.
Topics: Benzoates; beta-Thalassemia; Clinical Trials as Topic; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2007 |
Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
Topics: Benzoates; Chemistry, Pharmaceutical; Crystallography, X-Ray; Deferasirox; Deferiprone; Deferoxamine; Ferric Compounds; Humans; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Triazoles | 2007 |
Deferasirox : a review of its use in the management of transfusional chronic iron overload.
Topics: Animals; Benzoates; Blood Transfusion; Chronic Disease; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Transfusion Reaction; Triazoles | 2007 |
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Survival Rate; Transfusion Reaction; Treatment Outcome; Triazoles | 2007 |
Deferasirox for transfusion-related iron overload: a clinical review.
Topics: Administration, Oral; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2007 |
Clinical application of deferasirox: practical patient management.
Topics: Administration, Oral; Adult; Benzoates; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Contraindications; Creatinine; Deferasirox; Disease Management; Drug Eruptions; Gastrointestinal Diseases; Hematologic Diseases; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Transfusion Reaction; Triazoles | 2008 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles | 2008 |
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Diet; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Mutation; Phlebotomy; Pyridones; Triazoles | 2008 |
[Iron overload and iron chelation therapy in transfusion-dependent patients].
Topics: Benzoates; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Practice Guidelines as Topic; Triazoles | 2008 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Chelating Agents; Child; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Overload; Pyridones; Siderophores; Triazoles | 2008 |
Current approach to hemochromatosis.
Topics: Antimicrobial Cationic Peptides; Benzoates; Cation Transport Proteins; Deferasirox; Hemochromatosis; Hemochromatosis Protein; Hepcidins; Histocompatibility Antigens Class I; Humans; Iron Chelating Agents; Iron Overload; Membrane Proteins; Phlebotomy; Triazoles | 2008 |
76 trial(s) available for triazoles and Iron Overload
| Article | Year |
|---|---|
Efficacy and Tolerability of Twice-Daily Dosing Schedule of Deferasirox in Transfusion-Dependent Paediatric Beta-Thalassaemia Patients: A Randomized Controlled Study.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Thalassemia; Triazoles | 2023 |
Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).
Topics: Adult; Aged; Allografts; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Time Factors; Treatment Outcome; Triazoles; Young Adult | 2018 |
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients.
Topics: Adult; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Double-Blind Method; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Thalassemia; Triazoles; Young Adult | 2013 |
A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.
Topics: Adult; Aged; Benzoates; Consolidation Chemotherapy; Deferasirox; Early Termination of Clinical Trials; Female; Ferritins; Humans; Iatrogenic Disease; Induction Chemotherapy; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2013 |
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.
Topics: Benzoates; Blood Transfusion; Cross-Over Studies; Deferasirox; Double-Blind Method; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Thalassemia; Time Factors; Treatment Outcome; Triazoles | 2013 |
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelation Therapy; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Hydroxyurea; Incidence; Iron Chelating Agents; Iron Overload; Male; Pain Measurement; Phlebotomy; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult | 2013 |
The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload.
Topics: Adult; Allografts; Benzoates; Deferasirox; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Survival Rate; Transfusion Reaction; Triazoles | 2013 |
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Hydroxyurea; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult | 2013 |
A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox.
Topics: Adolescent; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Creatinine; Deferasirox; Female; Glomerular Filtration Rate; Humans; Iron Chelating Agents; Iron Overload; Kidney Diseases; Male; Metals; Prospective Studies; Triazoles | 2013 |
Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial.
Topics: Adolescent; Adult; Age Factors; Aged; Asian People; Benzoates; Child; Child, Preschool; China; Deferasirox; Female; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Prospective Studies; Thalassemia; Triazoles | 2013 |
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transfusion Reaction; Triazoles | 2014 |
Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Drug Eruptions; Female; Ferritins; Gastrointestinal Diseases; Humans; Iran; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2014 |
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferoxamine; Female; Ferritins; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Medication Adherence; Myocardium; Treatment Outcome; Triazoles; Troponin T; Young Adult | 2014 |
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.
Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles | 2014 |
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Transfusion; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2014 |
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.
Topics: Adult; Aged; Benzoates; Deferasirox; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Transplantation, Homologous; Treatment Outcome; Triazoles; Young Adult | 2014 |
Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Bone and Bones; Bone Density; Calcium; Chelation Therapy; Child; Child, Preschool; Deferasirox; Diabetes Mellitus; Diphosphonates; Female; Humans; Hypogonadism; Hypoparathyroidism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Puberty, Delayed; Retrospective Studies; Triazoles; Vitamin D | 2014 |
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Prospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia.
Topics: Adult; Benzoates; beta-Thalassemia; Biomarkers; Chelation Therapy; Creatinine; Deferasirox; Female; Ferritins; Glomerular Filtration Rate; Hemodynamics; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Renal Circulation; Transfusion Reaction; Triazoles; Young Adult | 2015 |
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Severity of Illness Index; Triazoles | 2015 |
Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.
Topics: Adult; Aged; Benzoates; Biomarkers; Deferasirox; Erythrocyte Indices; Female; Hemochromatosis; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Iron Chelating Agents; Iron Overload; Male; Membrane Proteins; Middle Aged; Mutation; Time Factors; Treatment Outcome; Triazoles | 2015 |
Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.
Topics: Anemia; Benzoates; Biomarkers; Deferasirox; Female; Ferritins; Follow-Up Studies; Humans; Iron; Iron Overload; Male; Transferrin; Triazoles | 2016 |
Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Erythrocyte Transfusion; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles | 2015 |
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Female; Heart; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Siderophores; Transfusion Reaction; Triazoles; Young Adult | 2015 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Stroke; Transfusion Reaction; Triazoles; Ultrasonography, Doppler, Transcranial | 2015 |
Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.
Topics: Adult; Benzoates; beta-Thalassemia; Chromatography, High Pressure Liquid; Deferasirox; Drug Administration Schedule; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles; Young Adult | 2015 |
Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Child; Child, Preschool; Deferasirox; Humans; Iron Overload; Liver; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2015 |
Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
Topics: Adult; Benzoates; beta-Thalassemia; Cardiomyopathies; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Stroke Volume; Treatment Outcome; Triazoles; Ventricular Function, Left; Young Adult | 2015 |
The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Male; Taiwan; Time Factors; Triazoles | 2015 |
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
Topics: Adolescent; Adult; Benzoates; Blood Transfusion; Chelation Therapy; Child; Deferasirox; Diarrhea; Drug Administration Schedule; Drug Dosage Calculations; Female; Follow-Up Studies; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Nausea; Thalassemia; Treatment Outcome; Triazoles | 2016 |
CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Treatment Outcome; Triazoles | 2016 |
Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
Topics: Adolescent; Adult; Aged; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Female; Ferritins; Heart Function Tests; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2017 |
One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Combined Modality Therapy; Deferasirox; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Phlebotomy; Prognosis; Prospective Studies; Triazoles | 2017 |
Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
Topics: Adolescent; Benzoates; Blood Glucose; Blood Transfusion; Chelation Therapy; Deferasirox; Drug Administration Schedule; Fasting; Female; Ferritins; Glucose Tolerance Test; Humans; Insulin Resistance; Insulin-Secreting Cells; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles; Young Adult | 2017 |
Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
Topics: Adolescent; Adult; Benzoates; Biomarkers; Chelation Therapy; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Prognosis; ROC Curve; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2017 |
A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Asian People; Benzoates; Blood Transfusion; Deferasirox; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Japan; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2008 |
Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
Topics: Aged; Aged, 80 and over; Benzoates; Bone Marrow; Deferasirox; Ferritins; Humans; Iron; Iron Overload; Liver; Magnetic Resonance Imaging; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Treatment Outcome; Triazoles | 2009 |
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Pyridones; Treatment Outcome; Triazoles; Young Adult | 2009 |
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Treatment Outcome; Triazoles; Young Adult | 2009 |
Deferasirox pharmacokinetics in patients with adequate versus inadequate response.
Topics: Adolescent; Adult; Anemia; Benzoates; Biological Availability; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Pharmacogenetics; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult | 2009 |
Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Triazoles; Young Adult | 2010 |
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Middle Aged; Prospective Studies; Thalassemia; Tissue Distribution; Triazoles; Young Adult | 2010 |
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Dose-Response Relationship, Drug; Female; Ferritins; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Myocardium; Prospective Studies; Triazoles; Young Adult | 2010 |
A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.
Topics: Adult; Benzoates; Deferasirox; Female; Ferritins; Heart; Hematopoietic Stem Cell Transplantation; Hemoglobins; Humans; Iron; Iron Overload; Liver; Male; Middle Aged; Phlebotomy; Transplantation, Homologous; Treatment Outcome; Triazoles | 2010 |
Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
Topics: Adult; Animals; Area Under Curve; Arylsulfatases; Benzoates; beta-Thalassemia; Cells, Cultured; Deferasirox; Feces; Female; Glucuronidase; Glucuronides; Hepatocytes; Humans; Hydroxylation; Iron Chelating Agents; Iron Overload; Male; Molecular Structure; Rats; Spectrometry, Mass, Electrospray Ionization; Sulfuric Acid Esters; Transfusion Reaction; Triazoles; Young Adult | 2010 |
Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Benzoates; Biomarkers; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Oxidative Stress; Time Factors; Treatment Outcome; Triazoles | 2010 |
The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Metabolic Clearance Rate; Myocardium; Treatment Outcome; Triazoles; Young Adult | 2010 |
Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle East; Patient Satisfaction; Prospective Studies; Triazoles | 2010 |
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles; Young Adult | 2010 |
Posttransplant oral iron-chelating therapy in patients with beta-thalassemia major.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Benzoates; beta-Thalassemia; Bone Marrow Transplantation; Child; Child, Preschool; Creatine; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles | 2010 |
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles | 2010 |
Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.
Topics: Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Down-Regulation; Female; Hemoglobin, Sickle; Heterozygote; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Radiography; Triazoles | 2011 |
Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Treatment Outcome; Triazoles; Young Adult | 2010 |
Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
Topics: Aged; Antimicrobial Cationic Peptides; Benzoates; Blood Transfusion; Deferasirox; Erythropoiesis; Female; Hepcidins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Oxidative Stress; Transferrin; Triazoles | 2011 |
Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Ferritins; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Prognosis; Treatment Outcome; Triazoles | 2011 |
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; Deferasirox; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2011 |
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
Topics: Adolescent; Anemia; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2011 |
[Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Dose-Response Relationship, Drug; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles | 2011 |
Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
Topics: Adolescent; Benzoates; Child; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Thalassemia; Triazoles; Young Adult | 2012 |
Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult | 2012 |
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Cardiomyopathies; Chelation Therapy; Child; Deferasirox; Drug Administration Schedule; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Magnetic Resonance Angiography; Triazoles | 2012 |
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Child; Deferasirox; Female; Follow-Up Studies; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutrophils; Prognosis; Prospective Studies; Survival Rate; Transfusion Reaction; Triazoles; Young Adult | 2012 |
Deferasirox therapy in children with Fanconi aplastic anemia.
Topics: Administration, Oral; Adolescent; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Fanconi Anemia; Female; Ferritins; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2012 |
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Algorithms; Benzoates; Blood Transfusion; Child; Deferasirox; Double-Blind Method; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Placebos; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles; Young Adult | 2012 |
Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Prospective Studies; Triazoles; Young Adult | 2012 |
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Creatinine; Deferasirox; Drug Eruptions; Female; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Treatment Outcome; Triazoles | 2013 |
Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Deferasirox; Deferoxamine; Drug Synergism; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Pilot Projects; Thalassemia; Transferrin; Triazoles; Young Adult | 2013 |
Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
Topics: Aged; Anemia, Iron-Deficiency; Area Under Curve; Benzoates; Biological Availability; Chromatography, Liquid; Deferasirox; Drug Administration Schedule; Drug Monitoring; Female; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Pilot Projects; Renal Dialysis; Renal Insufficiency, Chronic; Tandem Mass Spectrometry; Triazoles; Western Australia | 2013 |
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.
Topics: Adolescent; Adult; Area Under Curve; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Ferritins; Humans; Intestinal Absorption; Iron; Iron Overload; Male; Triazoles | 2003 |
Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Dose-Response Relationship, Drug; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Transfusion Reaction; Treatment Outcome; Triazoles | 2005 |
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles | 2006 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Administration Schedule; Female; Headache; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Respiratory Tract Infections; Treatment Outcome; Triazoles | 2007 |
Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Siderophores; Triazoles | 2006 |
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
Topics: Adolescent; Adult; Antidotes; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Iron Overload; Male; Middle Aged; Prospective Studies; Treatment Outcome; Triazoles | 2007 |
Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major.
Topics: Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Splenectomy; Triazoles | 2008 |
Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.
Topics: Adolescent; Adult; Area Under Curve; Benzoates; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Deferasirox; Eating; Female; Food; Food-Drug Interactions; Humans; Intestinal Absorption; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Spectrophotometry, Ultraviolet; Triazoles | 2008 |
163 other study(ies) available for triazoles and Iron Overload
| Article | Year |
|---|---|
[Deferasirox and Complex Proximal Tubulopathy. Presentation of two clinical cases].
Topics: Acute Kidney Injury; Adolescent; Anemia, Diamond-Blackfan; Benzoates; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Kidney; Male; Triazoles | 2021 |
Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Retrospective Studies; Triazoles | 2022 |
Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia.
Topics: Anemia, Aplastic; Benzoates; Creatinine; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Triazoles | 2022 |
Nephrolithiasis in two patients on iron chelation therapy: A case report.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Nephrolithiasis; Triazoles | 2023 |
Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Triazoles | 2021 |
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Risk Assessment; Risk Factors; Thalassemia; Triazoles | 2022 |
Outcome of iron reduction therapy in ex-thalassemics.
Topics: Adolescent; Allografts; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Iron; Iron Chelating Agents; Iron Overload; Male; Phlebotomy; Triazoles | 2021 |
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iran; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thalassemia; Triazoles; Young Adult; Zinc | 2021 |
Adrenal insufficiency: An emerging challenge in thalassemia?
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Adult; Benzoates; Blood Transfusion; Combined Modality Therapy; Deferasirox; Humans; Hypoglycemia; Hypogonadism; Hypothalamo-Hypophyseal System; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelolipoma; Pituitary-Adrenal System; Shock, Septic; Thalassemia; Triazoles | 2017 |
Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzoates; beta-Thalassemia; Cryoglobulinemia; Deferasirox; Deferoxamine; Elasticity Imaging Techniques; Female; Ferritins; Fluorenes; Hepatitis C, Chronic; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Quality of Life; Sofosbuvir; Triazoles; Viral Load | 2017 |
Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2018 |
Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England.
Topics: Adolescent; Adult; Aged; Benzoates; Child; Child, Preschool; Cohort Studies; Deferasirox; England; Female; General Practice; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Triazoles; Young Adult | 2018 |
Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.
Topics: Acetylcysteine; Animals; Benzoates; Colony-Forming Units Assay; Deferasirox; Disease Models, Animal; Flow Cytometry; Free Radical Scavengers; Hematopoiesis; Hematopoietic Stem Cells; Iron Chelating Agents; Iron Overload; Male; Mice, Inbred C57BL; Protective Agents; Reactive Oxygen Species; Reference Values; Reproducibility of Results; Time Factors; Treatment Outcome; Triazoles | 2017 |
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyridones; Retrospective Studies; Triazoles | 2018 |
Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
Topics: Adolescent; Adult; Benzoates; Blood Component Transfusion; Chelation Therapy; Child; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pyridones; Retrospective Studies; Thalassemia; Treatment Outcome; Triazoles; Turkey | 2018 |
Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Dialysis Solutions; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Treatment Outcome; Triazoles | 2018 |
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Topics: Anemia, Aplastic; Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Female; Iron Chelating Agents; Iron Overload; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Triazoles | 2018 |
A 3-year study of deferasirox therapy in sickle cell disease patients in Basra, Southern Iraq.
Topics: Abdominal Pain; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Creatinine; Deferasirox; Female; Ferritins; Humans; Iraq; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles | 2018 |
Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoates; Cell Line, Tumor; Chlorides; Crosses, Genetic; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; fas Receptor; Female; Ferric Compounds; Gene Expression Regulation, Leukemic; Iron; Iron Chelating Agents; Iron Overload; Iron-Dextran Complex; Leukemia L1210; Liver; Lymphoma, T-Cell; Mice; Mice, Inbred Strains; Neoplasm Proteins; Triazoles; Tumor Burden | 2013 |
Clinical characteristics and management of iron overload in 631 patients with chronic transfusion dependency: results from a multicentre, observational study.
Topics: Aged; Benzoates; Chelation Therapy; Comorbidity; Deferasirox; Disease Management; Erythrocyte Transfusion; Female; Ferritins; Guideline Adherence; Hematologic Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Practice Guidelines as Topic; Spain; Transfusion Reaction; Triazoles | 2014 |
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
Topics: Benzoates; Child, Preschool; Deferasirox; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Iron Overload; Markov Chains; Quality-Adjusted Life Years; Thalassemia; Transfusion Reaction; Triazoles | 2013 |
Loss of transfusion dependency following deferasirox treatment of iron overload in a woman with myelofibrosis and spherocytosis - a case report.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Primary Myelofibrosis; Spherocytosis, Hereditary; Treatment Outcome; Triazoles | 2013 |
Turning a blind eye to deferasirox's toxicity?
Topics: Age Factors; Benzoates; Cause of Death; Chronic Disease; Deferasirox; Drug Approval; Europe; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2013 |
Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.
Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles | 2013 |
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Liver; Male; Pyridones; Software; Triazoles; Young Adult | 2013 |
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Marketing; Patient Safety; Pyridones; Thalassemia; Triazoles | 2013 |
Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters.
Topics: Adult; Aging; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Disease Susceptibility; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Incidence; Iron Chelating Agents; Iron Overload; Italy; Kidney; Male; Nephrolithiasis; Retrospective Studies; Transfusion Reaction; Triazoles; Ultrasonography | 2014 |
Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration.
Topics: Adolescent; Adult; Benzoates; Biopsy, Needle; Calibration; Chelation Therapy; Child; Child, Preschool; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Prospective Studies; Treatment Outcome; Triazoles | 2014 |
Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Triazoles | 2014 |
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles | 2013 |
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Patient Compliance; Predictive Value of Tests; Pyridones; Risk; ROC Curve; Sampling Studies; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival?
Topics: Benzoates; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Pyridones; Transfusion Reaction; Triazoles | 2013 |
Korean guideline for iron chelation therapy in transfusion-induced iron overload.
Topics: Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Republic of Korea; Transfusion Reaction; Triazoles | 2013 |
Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT.
Topics: Benzoates; Deferasirox; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Transplantation, Homologous; Triazoles | 2014 |
Bad liver and a broken heart.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Myocardium; Triazoles | 2014 |
[The role of iron metabolism in myelodysplastic syndromes].
Topics: Anemia; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Triazoles | 2014 |
Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Overload; Male; Treatment Outcome; Triazoles | 2014 |
Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome.
Topics: Acute Disease; Administration, Oral; Aged; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Red-Cell Aplasia, Pure; Triazoles | 2014 |
Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzoates; Chemical and Drug Induced Liver Injury; Deferasirox; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Necrosis; Proportional Hazards Models; Retrospective Studies; Taiwan; Triazoles | 2014 |
Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
Topics: Benzoates; Blood Proteins; Deferasirox; Drug Monitoring; Female; Ferritins; Hematologic Neoplasms; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Multivariate Analysis; Prognosis; Protein Binding; Retrospective Studies; ROC Curve; Transfusion Reaction; Treatment Outcome; Triazoles | 2014 |
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Developing Countries; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Incidence; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thailand; Thalassemia; Transfusion Reaction; Triazoles; Young Adult | 2014 |
Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Topics: Adolescent; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Kidney Function Tests; Liver; London; Male; Medication Adherence; Retrospective Studies; Time Factors; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease.
Topics: Adult; Aged; Benzoates; Biomarkers; Cytokines; Deferasirox; Deferoxamine; Female; Ferritins; Follow-Up Studies; Gaucher Disease; Hepcidins; Hexosaminidases; Homeostasis; Humans; Inflammation; Iron; Iron Chelating Agents; Iron Overload; Macrophage Activation; Macrophages; Male; Middle Aged; Quality of Life; Triazoles | 2014 |
Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Topics: Administration, Oral; Adult; Aged; Anemia; Benzoates; Chelation Therapy; Deferasirox; Female; Hematopoiesis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzoates; Chromatography, High Pressure Liquid; Cohort Studies; Cytochrome P-450 Enzyme System; Deferasirox; Female; Genotype; Glucuronosyltransferase; Humans; Iron Overload; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Polymorphism, Single Nucleotide; Triazoles | 2015 |
A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Treatment Outcome; Triazoles | 2015 |
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Ferritins; Hematopoiesis; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Eruptions; Drug Therapy, Combination; Female; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Joint Diseases; Male; Prospective Studies; Proteinuria; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2015 |
Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles; Young Adult | 2015 |
Another Step Forward in Iron Chelation Therapy.
Topics: Anemia, Aplastic; Benzoates; Humans; Iron Overload; Liver; Myelodysplastic Syndromes; Triazoles | 2015 |
Deferasirox-TAT(47-57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine.
Topics: Animals; Benzoates; Blood-Brain Barrier; Cell Line; Cell Membrane; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Peptide Fragments; Rats; Solubility; tat Gene Products, Human Immunodeficiency Virus; Triazoles; Water | 2015 |
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Pyridones; Triazoles | 2015 |
Iron Chelation in Patients with Transfusion Dependent Thalassemia: An Insight on Response to Deferasirox.
Topics: Adolescent; Benzoates; Child; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Treatment Outcome; Triazoles; Young Adult | 2015 |
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Kaplan-Meier Estimate; Male; Medicare; Myelodysplastic Syndromes; Risk Reduction Behavior; Triazoles; United States | 2015 |
Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
Topics: Aged; Benzoates; Chelation Therapy; Deferasirox; Erythrocyte Indices; Erythropoiesis; Female; Fibrosis; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myeloproliferative Disorders; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2016 |
Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Female; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myocardium; Retrospective Studies; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles; Ventricular Function, Left; Young Adult | 2015 |
Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Ferritins; Follow-Up Studies; Hospitals, University; Humans; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2016 |
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles | 2016 |
[Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China].
Topics: Anemia, Aplastic; Benzoates; Blood Transfusion; China; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Prospective Studies; Triazoles | 2016 |
Deferasirox and children: From clinical trials to the real world.
Topics: Age Factors; Benzoates; beta-Thalassemia; Child; Clinical Trials as Topic; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Transfusion Reaction; Treatment Outcome; Triazoles | 2016 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Prevalence; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles | 2016 |
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Therapy, Combination; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Pyridones; Thalassemia; Transfusion Reaction; Triazoles | 2016 |
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles | 2017 |
A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
Topics: Acetylcysteine; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Benzoates; Brain; Deferasirox; Deferoxamine; Dendrites; Diet; Disease Models, Animal; Drug Therapy, Combination; Iron; Iron Chelating Agents; Iron Overload; Male; Mitochondrial Dynamics; Neurodegenerative Diseases; Phosphorylation; Random Allocation; Rats, Wistar; tau Proteins; Triazoles | 2016 |
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
Topics: Acetylcysteine; Animals; Benzoates; Cardiomyopathies; Cardiotonic Agents; Deferasirox; Deferiprone; Deferoxamine; Drug Combinations; Drug Synergism; Humans; Iron; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Malondialdehyde; Mitochondria; Pyridones; Rats; Rats, Wistar; Triazoles; Ventricular Function, Left | 2016 |
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; Deferiprone; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Proteinuria; Pyridones; Transfusion Reaction; Triazoles; Young Adult | 2017 |
Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2017 |
Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.
Topics: Adult; Anemia, Sickle Cell; Benzoates; Deferasirox; Erythropoietin; Female; Humans; Hypertension; Hypocalcemia; Iron Chelating Agents; Iron Overload; Kidney Failure, Chronic; Peritoneal Dialysis; Transfusion Reaction; Triazoles | 2008 |
Acute interstitial nephritis due to deferasirox: a case report.
Topics: Acute Disease; Benzoates; Deferasirox; Drug Hypersensitivity; Eosinophils; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Nephritis, Interstitial; Triazoles | 2008 |
Deferasirox in pyruvate kinase deficiency.
Topics: Adult; Benzoates; Deferasirox; Female; Humans; Iron Overload; Pyruvate Kinase; Treatment Outcome; Triazoles | 2009 |
Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2008 |
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.
Topics: Benzoates; Deferasirox; Deferiprone; Drug Therapy, Combination; Heart; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2008 |
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
Topics: Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gerbillinae; Heart; Iron Overload; Liver; Organ Size; Treatment Outcome; Triazoles | 2008 |
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug Industry; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Truth Disclosure | 2008 |
Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
Topics: Administration, Oral; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Hematology; Hospitals; Humans; Infant; Infant, Newborn; Iron Chelating Agents; Iron Overload; Male; Pediatrics; Triazoles | 2009 |
Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2009 |
Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Benzoates; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Triazoles | 2009 |
Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Overload; Pyridones; Siderophores; Triazoles; Vibrio Infections; Vibrio vulnificus | 2009 |
Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
Topics: Animals; Benzoates; Cardiotonic Agents; Deferasirox; Extracellular Signal-Regulated MAP Kinases; Gerbillinae; Heart; Iron; Iron Chelating Agents; Iron Overload; Male; MAP Kinase Kinase 4; Myocardium; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Triazoles | 2009 |
Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
Topics: Administration, Oral; Anemia; Benzoates; Cost-Benefit Analysis; Deferasirox; Drug Costs; Economics, Pharmaceutical; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Medication Adherence; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2009 |
Iron chelation therapy in myelodysplastic syndrome - Cui bono?
Topics: Aged; Benzoates; Biomarkers; Chelation Therapy; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Life Expectancy; Middle Aged; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2009 |
Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Triazoles | 2010 |
Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Child; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Parents; Patient Compliance; Surveys and Questionnaires; Triazoles | 2009 |
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.
Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Negative Bacterial Infections; Humans; Iron Chelating Agents; Iron Overload; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Prevalence; Pyridones; Thalassemia; Triazoles | 2009 |
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Humans; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles | 2009 |
Deferasirox (Exjade) for the treatment of iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Rare Diseases; Thalassemia; Triazoles | 2009 |
Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Erythrocytes; Erythroid Cells; Ferritins; Flow Cytometry; Humans; In Vitro Techniques; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Phosphatidylserines; Pyridones; Reactive Oxygen Species; Reticulocytes; Triazoles | 2010 |
Deferasirox treatment may be associated with reversible renal Fanconi syndrome.
Topics: Adolescent; Benzoates; Child; Deferasirox; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Iron Overload; Kidney; Male; Transfusion Reaction; Triazoles | 2010 |
Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2010 |
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.
Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Overload; Pyridones; Triazoles | 2009 |
Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.
Topics: Aged; Anemia; Benzoates; Chronic Disease; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Radiography; Thrombocytopenia; Transfusion Reaction; Triazoles | 2010 |
Ability of deferasirox to bind iron during measurement of iron.
Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Triazoles | 2010 |
Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.
Topics: Adenosine Triphosphate; Animals; Benzoates; Biological Transport; Cell Line; Cell Polarity; Deferasirox; Deferoxamine; Dogs; Epithelial Cells; Exocytosis; Iron; Iron Chelating Agents; Iron Overload; Iron Radioisotopes; Kidney; Models, Biological; Pyridones; Siderophores; Temperature; Triazoles | 2010 |
Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Deferasirox; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Time Factors; Triazoles; Ventricular Function, Left; Young Adult | 2010 |
Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.
Topics: Aging; Animals; Apoptosis; Benzoates; Body Weight; Deferasirox; Heart; In Situ Nick-End Labeling; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Myocytes, Cardiac; Organ Size; Rats; Rats, Inbred F344; Trace Elements; Triazoles | 2010 |
Iron chelation therapy in myelodysplastic syndromes.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Quality-Adjusted Life Years; Siderophores; Treatment Outcome; Triazoles | 2010 |
A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application.
Topics: Benzoates; Blood Specimen Collection; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Iron Chelating Agents; Iron Overload; Quality Control; Reference Standards; Reproducibility of Results; Solvents; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2010 |
Acute renal failure and Fanconi syndrome due to deferasirox.
Topics: Acute Kidney Injury; Aged; Benzoates; Chronic Disease; Deferasirox; Fanconi Syndrome; Humans; Iron Chelating Agents; Iron Overload; Kidney; Male; Triazoles | 2010 |
Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Siderophores; Survival Rate; Thalassemia; Treatment Outcome; Triazoles; Young Adult | 2010 |
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Young Adult | 2010 |
The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Topics: Anti-Infective Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Infections; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles | 2010 |
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; Deferoxamine; Female; Greece; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Spectroscopy; Male; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2010 |
Pathogenesis and management of iron toxicity in thalassemia.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Reactive Oxygen Species; Thalassemia; Transferrin; Transfusion Reaction; Triazoles | 2010 |
Delineating parameters of iron overload in MDS patients treated with deferasirox.
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles | 2010 |
Iron chelation therapy for patients with sickle cell disease and iron overload.
Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Erythrocyte Transfusion; Humans; Infusion Pumps; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Male; Pain; Patient Compliance; Pyridones; Sensation Disorders; Social Isolation; Triazoles; Young Adult; Zinc | 2010 |
Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Insurance Claim Review; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Myelodysplastic Syndromes; Quality-Adjusted Life Years; Siderophores; State Medicine; Survival Analysis; Triazoles; United Kingdom | 2010 |
A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
Topics: Adult; Aged; Amino Acid Substitution; Benzoates; Creatinine; Deferasirox; Dose-Response Relationship, Drug; Female; Ferritins; Hemochromatosis; Homozygote; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Phlebotomy; Safety; Transferrin; Triazoles | 2010 |
Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.
Topics: Anemia, Aplastic; Benzoates; Child; Deferasirox; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Male; Severity of Illness Index; Transfusion Reaction; Triazoles | 2010 |
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Pyridones; Retrospective Studies; Siderophores; Triazoles; Ventricular Function; Young Adult | 2011 |
Iron-induced cardiac damage: role of apoptosis and deferasirox intervention.
Topics: Animals; Apoptosis; Benzoates; Deferasirox; Gerbillinae; Iron; Iron Chelating Agents; Iron Overload; Male; Myocardium; Triazoles | 2011 |
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Prognosis; Prospective Studies; Triazoles; Ventricular Function, Left; Young Adult | 2011 |
HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox.
Topics: Benzoates; Brazil; Cation Transport Proteins; Combined Modality Therapy; Deferasirox; Exons; Gene Amplification; Hemochromatosis; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Hypogonadism; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Membrane Proteins; Phlebotomy; Polymorphism, Single Nucleotide; Receptors, Transferrin; Stroke Volume; Triazoles; Young Adult | 2010 |
Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Topics: Administration, Oral; Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Drug Administration Schedule; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Maximum Tolerated Dose; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2011 |
Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.
Topics: Adolescent; Benzoates; beta-Thalassemia; Deferasirox; Fanconi Syndrome; Hospitalization; Humans; Iron Chelating Agents; Iron Overload; Kidney; Male; Transfusion Reaction; Triazoles | 2011 |
The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Heart; Humans; Iron Chelating Agents; Iron Overload; Kidney; Liver; Male; Prospective Studies; Treatment Outcome; Triazoles; Young Adult | 2011 |
Unrelated hematopoietic stem cell transplantation in a patient with congenital dyserythropoietic anemia and iron overload.
Topics: Anemia, Dyserythropoietic, Congenital; Benzoates; Bone Marrow Transplantation; Child, Preschool; Deferasirox; Deferoxamine; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles; Unrelated Donors | 2012 |
Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Female; Humans; India; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles | 2011 |
Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
Topics: Adult; Anemia, Aplastic; Benzoates; Bone Marrow Transplantation; Deferasirox; Ferritins; Hemochromatosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2011 |
Reversible Fanconi syndrome in a pediatric patient on deferasirox.
Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Erythrocyte Transfusion; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2011 |
Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Benzoates; Caspase 3; Chemical and Drug Induced Liver Injury; Deferasirox; Disease Models, Animal; DNA Fragmentation; Ferritins; Gerbillinae; Iron Chelating Agents; Iron Overload; Iron-Dextran Complex; Male; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Translational Research, Biomedical; Triazoles | 2011 |
A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients.
Topics: Benzoates; Deferasirox; Drug-Related Side Effects and Adverse Reactions; Ethics, Medical; Ethics, Research; Humans; Iron Overload; Triazoles | 2011 |
Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Treatment Outcome; Triazoles | 2011 |
Challenges of adherence and persistence with iron chelation therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Dosage Forms; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Patient Care Team; Patient Compliance; Pyridones; Time Factors; Triazoles | 2011 |
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transfusion Reaction; Triazoles | 2012 |
Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
Topics: Adolescent; Adult; Benzoates; Deferasirox; Female; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Kidney; Leukemia; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Phlebotomy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Triazoles; Young Adult | 2012 |
Safety of deferasirox in sickle cell disease patients with co-existing liver impairment.
Topics: Anemia, Sickle Cell; Benzoates; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles | 2012 |
[Marked improvement of anemia during treatment with deferasirox in patients with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes].
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2012 |
Iron overload during follow-up after tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Child; Child, Preschool; Creatinine; Deferasirox; Ferritins; Follow-Up Studies; Humans; Infant; Iron Chelating Agents; Iron Overload; Neuroblastoma; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transfusion Reaction; Transplantation, Autologous; Triazoles | 2012 |
Determination of ferritin and hemosiderin iron in patients with normal iron stores and iron overload by serum ferritin kinetics.
Topics: Anemia; Benzoates; Biomarkers; Computer Simulation; Deferasirox; Female; Ferritins; Hemochromatosis; Hemosiderin; Hepatitis C, Chronic; Humans; Iron; Iron Chelating Agents; Iron Overload; Japan; Kinetics; Liver; Male; Middle Aged; Models, Biological; Triazoles | 2012 |
Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.
Topics: Administration, Oral; Adolescent; Age Factors; Benzoates; Child; Deferasirox; Female; Glomerular Filtration Rate; Humans; Inulin; Iron Chelating Agents; Iron Overload; Kidney Diseases; Kidney Glomerulus; Kidney Tubules, Proximal; Male; Prospective Studies; Time Factors; Transfusion Reaction; Triazoles | 2012 |
First report of drug-induced esophagitis by deferasirox.
Topics: Benzoates; Deferasirox; Esophagitis; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2012 |
The administration of deferasirox in an iron-overloaded dialysis patient.
Topics: Benzoates; Deferasirox; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Triazoles | 2013 |
Thalassemia: cardiac iron and chelators.
Topics: Benzoates; Deferasirox; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Myocardium; Thalassemia; Triazoles; Ventricular Function, Left | 2012 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Antigens, CD; Benzoates; Case-Control Studies; Deferasirox; Deoxyguanosine; DNA Damage; Erythrocyte Transfusion; Ferritins; Genome, Human; Humans; Iron Chelating Agents; Iron Overload; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Prospective Studies; Reactive Oxygen Species; Statistics, Nonparametric; Triazoles | 2012 |
Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats.
Topics: Animals; Ascorbic Acid; Ascorbic Acid Deficiency; Benzoates; Deferasirox; Guinea Pigs; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Mononuclear Phagocyte System; Myocardium; Rats; Rats, Mutant Strains; Triazoles | 2012 |
Iron out for nontransfused thalassemia.
Topics: Benzoates; Deferasirox; Female; Humans; Iron Overload; Male; Thalassemia; Triazoles | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles | 2012 |
Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Female; Greece; Humans; Hypercalciuria; Hyperuricemia; Iron Chelating Agents; Iron Overload; Male; Nephrolithiasis; Postoperative Complications; Pyridones; Splenectomy; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Blood Transfusion; Cohort Studies; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Drug Costs; Humans; Injections, Subcutaneous; Iron Chelating Agents; Iron Overload; Medication Adherence; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Triazoles; United Kingdom | 2012 |
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Cholelithiasis; Clinical Trials, Phase III as Topic; Creatinine; Deferasirox; Edema; Ethnicity; Female; Ferritins; Gastrointestinal Diseases; Hematologic Diseases; Hepatitis, Viral, Human; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Liver; Magnetic Resonance Imaging; Male; Multicenter Studies as Topic; Prospective Studies; Thalassemia; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
Topics: Adult; Anemia, Aplastic; Benzoates; Chelation Therapy; Deferasirox; Erythrocyte Transfusion; Female; Ferritins; Hematopoiesis; Humans; Immunosuppressive Agents; Iron; Iron Chelating Agents; Iron Overload; Male; Platelet Transfusion; Transfusion Reaction; Triazoles | 2013 |
Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
Topics: Adolescent; Adult; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2012 |
Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients.
Topics: Adult; Anemia, Sickle Cell; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Pilot Projects; Triazoles | 2013 |
Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Cost-Benefit Analysis; Cross-Sectional Studies; Deferasirox; Deferoxamine; Drug Costs; Female; Humans; Infusions, Intravenous; Iran; Iron Chelating Agents; Iron Overload; Male; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Transfusion Reaction; Treatment Outcome; Triazoles | 2013 |
Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Cell Count; Cell Proliferation; Cohort Studies; Deferasirox; Erythroid Precursor Cells; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Triazoles | 2013 |
ICL670A: preclinical profile.
Topics: Administration, Oral; Animals; Benzoates; beta-Thalassemia; Callithrix; Deferasirox; Dogs; Drug Evaluation, Preclinical; Drug Tolerance; Humans; Iron; Iron Chelating Agents; Iron Overload; Molecular Structure; Rats; Triazoles | 2002 |
Do we need more iron-chelating drugs?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles | 2003 |
Iron chelation therapy.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Isoniazid; Pyridones; Pyridoxal; Survival; Triazoles | 2005 |
The Egyptian experience with oral iron chelators.
Topics: Benzoates; Deferasirox; Deferiprone; Egypt; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Treatment Outcome; Triazoles | 2005 |
Molecule of the month. Deferasirox.
Topics: Benzoates; Chelating Agents; Deferasirox; Humans; Iron Overload; Multicenter Studies as Topic; Transfusion Reaction; Triazoles | 2005 |
The oral chelator deferasirox--a new perspective for patients with iron overload.
Topics: Benzoates; Clinical Trials as Topic; Deferasirox; Half-Life; Humans; Iron Chelating Agents; Iron Overload; Triazoles | 2006 |
Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Disease Models, Animal; Female; Gerbillinae; Heart; Iron; Iron Chelating Agents; Iron Overload; Liver; Organ Size; Pyridones; Triazoles | 2006 |
Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Blood Transfusion; Cost-Benefit Analysis; Deferasirox; Delivery of Health Care; Drug Administration Schedule; Drug Utilization Review; Economics, Pharmaceutical; Humans; Infusions, Intravenous; Insurance Claim Review; Iron Chelating Agents; Iron Overload; Markov Chains; Treatment Outcome; Triazoles; United States | 2007 |
[Post transfusionnal iron overload].
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Pyridones; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.
Topics: Animals; Benzoates; Cardiomyopathies; Deferasirox; Disease Models, Animal; Drug Administration Schedule; Female; Gerbillinae; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Triazoles | 2007 |
Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.
Topics: Atrophy; Benzoates; Biopsy; Brain; Ceruloplasmin; Chelation Therapy; Chorea; Deferasirox; Diagnosis, Differential; Disease Progression; Female; Ferritins; Gait Disorders, Neurologic; Humans; Iron Overload; Liver; Magnetic Resonance Imaging; Middle Aged; Muscle Spasticity; Muscle, Skeletal; Neurodegenerative Diseases; Neurologic Examination; Neuropsychological Tests; Spleen; Triazoles | 2008 |
Deferasirox: for iron overload: only a third-line option.
Topics: Administration, Oral; Benzoates; France; Humans; Iron Chelating Agents; Iron Overload; Transfusion Reaction; Triazoles | 2007 |
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Decision Support Techniques; Deferasirox; Deferiprone; Deferoxamine; Hematology; Humans; Iron Chelating Agents; Iron Overload; Liver; Practice Guidelines as Topic; Pyridones; Siderophores; Triazoles | 2008 |
Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
Topics: Adult; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Female; Humans; Interviews as Topic; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Siderophores; State Medicine; Triazoles; United Kingdom | 2008 |
Chelator-induced iron excretion in iron-overloaded marmosets.
Topics: Animals; Benzoates; Callithrix; Cebus; Chelating Agents; Deferasirox; Dose-Response Relationship, Drug; Edetic Acid; Feces; Female; Iron; Iron Overload; Liver; Male; Models, Animal; Pyridines; Triazoles | 2000 |
ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Topics: Animals; Benzoates; Bile; Cells, Cultured; Deferasirox; Deferoxamine; Drug Evaluation, Preclinical; Erythrocyte Transfusion; Erythrocytes, Abnormal; Feces; Female; Ferritins; Heart; Hepatocytes; Hot Temperature; Injections, Intravenous; Iron Chelating Agents; Iron Overload; Iron Radioisotopes; Liver; Mice; Molecular Structure; Mononuclear Phagocyte System; Myocardium; Organ Specificity; Rats; Rats, Wistar; Tissue Distribution; Transfusion Reaction; Triazoles; Urine | 2001 |
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.
Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine; Drug Stability; Humans; Hydrogen-Ion Concentration; Iron; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Reproducibility of Results; Spectrophotometry, Ultraviolet; Temperature; Thalassemia; Triazoles | 2001 |